Steven Sterin - Senior Vice President and Chief Financial Officer
Analyst · Sergey Vasnetsov with Lehman Brothers. Please proceed
Thanks Dave. I'll start by turning to page 8 in the PowerPoint presentation that's posted on our website. Our net sales were approximately $1.8 billion, a 19% increase from last year, driven by higher pricing and continued strong demand, higher volumes from our integrated complex in Nanjing as well as favorable currency impact. Operating profit rose 14% to $234 million. Our overall higher prices, volumes and productivity programs were able to more than offset significantly higher raw material and energy costs, as well as spending related to our China expansion. Net earnings were $145 million versus $201 million in the first quarter of last year. Last year's results included $79 million of earnings from disc ops related to the sale of the oxo alcohol business and the closure of the Edmonton methanol facility. Our adjusted EPS was a record $1.06 per share. This is a 38% increase from last year's results. This quarter's results included a $0.06 per share benefit from the share repurchase programs executed over the last year. This benefit was partially offset by $0.02 of year-over-year option dilution. Operating EBITDA was also a record of $381 million, a 21% increase versus last year. Let's now turn to the results of each of our businesses, starting with advanced engineered materials on page 9. Net sales were $294 million, up 12% from last year's results, a 6% volume growth as well as positive effects from currency. We continued to see good growth in this business and we are also beginning to see the benefits of our strategy for growth in China, which is a key driver in the increased sales for the quarter. The increased net sales were partially offset by lower average pricing as a result of geographic and product mix. Operating EBITDA was down 10%, year-over-year, as high raw material and energy costs continued to pressure margins. We also had lower earnings in our equity affiliates, which face the same margin pressures. On page 10, net sales for consumer specialties were $282 million. This is a 5% increase over last year's results. The increase was primarily driven by higher pricing and continued strong global demand as well as favorable currency. The quarter also included additional sales and profit from the Acetate Products Limited acquisition which closed in February of last year. The lower volumes this quarter were associated with our strategic decision to shift flake production to our China ventures, following the closure of our Edmonton facility. Keep in mind that you will see the positive impact of this strategic shift in the form of increased dividends from these ventures in the second quarter. Operating EBITDA was $65 million, up 8% from last year, as the higher pricing along with the synergies we've captured from our APL acquisition, contributed to the improved results. We are very pleased with the success of the APL integration, and at this point believe that we have achieved our expected level of synergy captured from this business. Turning now to industrial specialties on page 11; net sales in these businesses were $365 million, a 5% increase from last year's results. Higher pricing and continued strong global demand and foreign currency drove the increased sales. These increases were offset by lower overall volumes in the quarter, principally due to three items; continued softness in the U.S. housing and construction segments, some residue impact from the loss businesses associated with last year's Acetyl's force majeure and a tough comp due to strong demand in Germany last year in anticipation of a tax law change. Additionally, as part of the segment's revitalization efforts, we focused our selling efforts on higher value-added applications and consequently moved away from some segments. Operating EBITDA however was up significantly, 38% this quarter as increased revenue more than offset the higher raw material cost. On page 12, Acetyl Intermediates net sales were approximately $1.1 billion, up 31% from last year and a record for the quarter. If you break this down, we saw a volume growth of 8%, pricing of 17% and favorable currency of 6%. The additional volume was from our acetic acid unit in Nanjing that successfully started production last year and continues to run at very high operating rates. Operating EBITDA was $246 million, a 41% improvement over last year as the favorable industry dynamics and higher dividends from our Ibn Sina cost affiliate, more than offset higher raw material and energy costs. Now, let's turn to our equity and cost investment performance on page 13. The income statement impact for the first quarter is shown in the chart on the left. Our earnings impact was $38 million, a 15% improvement over last year's results. Our Ibn Sina methanol and MTBE cost affiliate more than offset the lower earnings from our Asian equity affiliates. We also see that we had higher cash dividends from our cost affiliates driven by the performance of Ibn Sina and higher dividends from our equity investments primarily timing away. Keep in mind that the methanol earnings from Ibn Sina provide a natural hedge to a new identical exposure in our AEM businesses, which has seen margin pressures of late. On page 14, you can see our continued strong cash flow, reflected by a $94 million increase in net operating cash flows from continuing operations. Capital expenditures were $32 million higher as we near completion of our capital spend in Nanjing. Our adjusted free cash flow was $67 million in the quarter, an increase of $54 million from last year, as result of our strong operating performance, lower cash taxes and higher dividends. Let's now turn to page 15 where we summarize our business outlook and 2008 guidance. As Dave mentioned earlier, we have increased our 2008 for adjusted EPS and operating EBITDA. We now expect adjusted EPS to be between $3.60 and $3.85 a share and operating EBITDA to be between $1.355 billion and $1.415 billion. This guidance is based on our adjusted tax rate of 26%. I won't read you the business specific drivers, but in summary, our outlook remains relatively unchanged for all of our businesses. The one exception is our view for acetic acid pricing in Asia, which as Dave highlighted is expected to remain at alleviative levels throughout 2008 versus our prior outlook which had factored in moderating price levels in the second half of the year. Slide 16 highlights some of the additional components of our outlook. As we mentioned earlier, Ibn Sina has had a strong performance so far this year. So we are updating our full year outlook for affiliate income to $200 million to $215 million. We are increasing our expectation for net interest expense by $10 million, due in large part the currency translation related to the strong euro. Our full year outlook for diluted share count is 167 million shares, which is where we ended the first quarter. We haven't assumed a number for future share repurchases but we do intend to continue to be in the market opportunistically during the remainder of the year. Our current guidance reflects only the share repurchases made today, which is approximately $60 million or 1.6 million shares. The current guidance assumes that the remaining authorization stays on the balance sheet's cash. As we progress with our program, we'll update you quarterly on what to expect for share count and net interest expense. Depreciation and amortization is expected to be up slightly primarily related to foreign currency exchange. A last change is cash taxes, which are expected to be approximately $25 million higher, principally driven by our increased earnings outlook. In total, we consider these changes and our increased earnings; our adjusted free cash flow expectation has increased to $550 million to $600 million for the year. Our strong cash generation is a differentiator in our space, and as Dave said a source of significant value creation opportunity and sustainable earnings growth for the company. With that, I'll like turn it back over to Mark to open the Q&A.